NL-OMON32633已完成不适用
A multi-center, single-blinded, randomized, controlled, parallel-group study to evaluate the wearing comfort of two different placebo intrauterine systems FR01 and FR20 compared to a placebo T-frame intrauterine system for 3 cycles in healthy women aged 18-40 years - FR01 and FR20 IUS wearing study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy Female subject
- •Age 18-40 years (inclusive)
- •History of regular cyclic menstrual periods at baseline (cycle length 21 to 35 days)
- •Women using any COC for contraception with a monthly regimen before the study entry.
- •Confirmed uterine sound depth of 6 to 10 cm
排除标准
- •Pregnancy or lactation
- •Nulliparous
- •Congenital or acquired uterine anomaly
- •Vaginal or cesarean delivery within 8 weeks prior to insertion
研究者
相似试验
已完成
1 期
A single-center, randomized, single-blinded, controlled, pilot study to investigate the delivery of adalimumab after subcutaneous injection with a needle free injection device compared to injection with a syringeHealthy VolunteersDRKS00007903IIS Innovative Injektions-Systeme GmbH & Co. KG36
进行中（未招募）
不适用
A multi-centre, randomised, double-blinded, controlled, dose-escalation trial on safety and efficacy of activated recombinant FVII analogue (NN1731) in the treatment of joint bleeds in congenital haemophilia patients with inhibitors - NDHaemophilia A with antifactor VIII and Haemophilia B with antifactor IXMedDRA version: 9.1Level: LLTClassification code 10056492Term: Haemophilia A with anti factor VIIIEUCTR2006-004879-35-ITOVO NORDISK50
进行中（未招募）
1 期
A multi-centre, randomised, double-blinded, controlled, dose-escalation trial on safety and efficacy of activated recombinant FVII analogue (NN1731) in the treatment of joint bleeds in congenital haemophilia patients with inhibitors.Trial phase: 2Haemophilia A with anti factor VIII and Haemophilia B with anti factor IXMedDRA version: 9.1Level: LLTClassification code 10056492Term: Haemophilia A with anti factor VIIIMedDRA version: 9.1Level: LLTClassification code 10056494Term: Haemophilia B with anti factor IXEUCTR2006-004879-35-FRovo Nordisk A/S
进行中（未招募）
1 期
A multi-centre, randomised, double-blinded, controlled, dose-escalation trial on safety and efficacy of activated recombinant FVII analogue (NN1731) in the treatment of joint bleeds in congenital haemophilia patients with inhibitors.Trial phase: 2Haemophilia A with anti factor VIII and Haemophilia B with anti factor IXMedDRA version: 9.1Level: LLTClassification code 10056492Term: Haemophilia A with anti factor VIIIMedDRA version: 9.1Level: LLTClassification code 10056494Term: Haemophilia B with anti factor IXEUCTR2006-004879-35-HUovo Nordisk A/S
进行中（未招募）
1 期
A multi-centre, randomised, double-blinded, controlled, dose-escalation trial on safety and efficacy of activated recombinant FVII analogue (NN1731) in the treatment of joint bleeds in congenital haemophilia patients with inhibitors.Trial phase: 2Haemophilia A with anti factor VIII and Haemophilia B with anti factor IXMedDRA version: 9.1Level: LLTClassification code 10056492Term: Haemophilia A with anti factor VIIIMedDRA version: 9.1Level: LLTClassification code 10056494Term: Haemophilia B with anti factor IXEUCTR2006-004879-35-GBovo Nordisk A/S70